{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:44:30Z","timestamp":1789598670425,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,9]]},"DOI":"10.7759\/cureus.44969","type":"journal-article","created":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T06:57:03Z","timestamp":1694329023000},"source":"Crossref","is-referenced-by-count":2,"title":["Unravelling the Interplay: Exploring the Influence of Previous Hepatitis B Virus, Hepatitis A Virus, and Hepatitis E Virus Infections on Non-alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Vinay","family":"Narladkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket S","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarupa","family":"Chakole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket G","family":"Pathade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Yelne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice J","year":"2018","unstructured":"Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018, 18:245-50. 10.7861\/clinmedicine.18-3-245","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict M","year":"2017","unstructured":"Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017, 9:715-32. 10.4254\/wjh.v9.i16.715","journal-title":"World J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031823","article-title":"Hepatitis A virus and hepatitis E virus: emerging and re-emerging enterically transmitted hepatitis viruses","volume":"9","author":"Lemon SM","year":"2019","unstructured":"Lemon SM, Walker CM. Hepatitis A virus and hepatitis E virus: emerging and re-emerging enterically transmitted hepatitis viruses. Cold Spring Harb Perspect Med. 2019, 9:031823. 10.1101\/cshperspect.a031823","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22364","article-title":"Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"8","author":"Xiong J","year":"2017","unstructured":"Xiong J, Zhang H, Wang Y, et al.. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017, 8:107295-302. 10.18632\/oncotarget.22364","journal-title":"Oncotarget"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay-related mechanisms underlying liver disease progression","volume":"13","author":"Tourkochristou E","year":"2022","unstructured":"Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay-related mechanisms underlying liver disease progression. Front Immunol. 2022, 13:965548. 10.3389\/fimmu.2022.965548","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.814209","article-title":"Non-alcoholic fatty liver disease in HIV\/HBV patients - a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the hepatokine\/adipokine axis breakdown","volume":"13","author":"Iacob SA","year":"2022","unstructured":"Iacob SA, Iacob DG. Non-alcoholic fatty liver disease in HIV\/HBV patients - a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the hepatokine\/adipokine axis breakdown. Front Endocrinol (Lausanne). 2022, 13:814209. 10.3389\/fendo.2022.814209","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","unstructured":"Hepatitis B. (2023). Accessed. August 18, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001359","article-title":"Hepatitis B virus: infection, liver disease, carcinogen or syndemic threat? Remodelling the clinical and public health response","volume":"2","author":"Matthews PC","year":"2022","unstructured":"Matthews PC, Maponga T, Ghosh I, et al.. Hepatitis B virus: infection, liver disease, carcinogen or syndemic threat? Remodelling the clinical and public health response. PLOS Glob Public Health. 2022, 2:e0001359. 10.1371\/journal.pgph.0001359","journal-title":"PLOS Glob Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari FV","year":"2010","unstructured":"Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010, 58:258-66. 10.1016\/j.patbio.2009.11.001","journal-title":"Pathol Biol (Paris)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan A","year":"2015","unstructured":"Tan A, Koh S, Bertoletti A. Immune response in hepatitis B virus infection. Cold Spring Harb Perspect Med. 2015, 5:a021428. 10.1101\/cshperspect.a021428","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.636897","article-title":"Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang J","year":"2021","unstructured":"Zhang J, Ling N, Lei Y, Peng M, Hu P, Chen M. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B. Front Microbiol. 2021, 12:636897. 10.3389\/fmicb.2021.636897","journal-title":"Front Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28917","article-title":"Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study","volume":"65","author":"Joo EJ","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017, 65:828-35. 10.1002\/hep.28917","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040741","article-title":"Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review","volume":"11","author":"Sivasudhan E","year":"2022","unstructured":"Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. Cells. 2022, 11:10.3390\/cells11040741","journal-title":"Cells"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen L","year":"2018","unstructured":"Chen L, Deng H, Cui H, et al.. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018, 9:7204-18. 10.18632\/oncotarget.23208","journal-title":"Oncotarget"},{"key":"ref15","unstructured":"Hepatitis A. (2023). Accessed. August 18, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-a."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i14.1405","article-title":"Viral hepatitis: Past, present, and future","volume":"28","author":"Odenwald MA","year":"2022","unstructured":"Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol. 2022, 28:1405-29. 10.3748\/wjg.v28.i14.1405","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020, 5:16. 10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref19","article-title":"Innate immune system","author":"Aristiz\u00e1bal B","year":"2013","unstructured":"Aristiz\u00e1bal B, Gonz\u00e1lez \u00c1. Innate immune system. Autoimmunity: From Bench to Bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al. (ed): El Rosario University Press, Bogota, Colombia; 2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459455\/#__NBK459455_dtls__:"},{"key":"ref20","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos P","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009, 13:9-19.","journal-title":"Hippokratia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13482996","article-title":"Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ","volume":"6","author":"Guinane CM","year":"2013","unstructured":"Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013, 6:295-308. 10.1177\/1756283X13482996","journal-title":"Therap Adv Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3945\/jn.116.240754","article-title":"Factors influencing the gut microbiota, inflammation, and type 2 diabetes","volume":"147","author":"Wen L","year":"2017","unstructured":"Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. J Nutr. 2017, 147:1468S-75S. 10.3945\/jn.116.240754","journal-title":"J Nutr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13933","article-title":"Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study","volume":"39","author":"Zhu L","year":"2019","unstructured":"Zhu L, Jiang J, Zhai X, et al.. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study. Liver Int. 2019, 39:70-80. 10.1111\/liv.13933","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i16.1691","article-title":"From hepatitis A to E: a critical review of viral hepatitis","volume":"27","author":"Castaneda D","year":"2021","unstructured":"Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: a critical review of viral hepatitis. World J Gastroenterol. 2021, 27:1691-715. 10.3748\/wjg.v27.i16.1691","journal-title":"World J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i44.9674","article-title":"Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV","volume":"22","author":"Lonardo A","year":"2016","unstructured":"Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016, 22:9674-93. 10.3748\/wjg.v22.i44.9674","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cld.716","article-title":"Diagnostic challenges of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"11","author":"Cleveland E","year":"2018","unstructured":"Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018, 11:98-104. 10.1002\/cld.716","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-22. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/145754","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease","volume":"2012","author":"Obika M","year":"2012","unstructured":"Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012, 2012:145754. 10.1155\/2012\/145754","journal-title":"Exp Diabetes Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/725468","article-title":"Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"26","author":"Beaton MD","year":"2012","unstructured":"Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012, 26:353-7. 10.1155\/2012\/725468","journal-title":"Can J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.343","article-title":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity","volume":"33","author":"Kwak MS","year":"2018","unstructured":"Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med. 2018, 33:64-74. 10.3904\/kjim.2017.343","journal-title":"Korean J Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413219","article-title":"The new therapeutic approaches in the treatment of non-alcoholic fatty liver disease","volume":"22","author":"Filipovic B","year":"2021","unstructured":"Filipovic B, Lukic S, Mijac D, et al.. The new therapeutic approaches in the treatment of non-alcoholic fatty liver disease. Int J Mol Sci. 2021, 22:10.3390\/ijms222413219","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo A","year":"2021","unstructured":"Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther. 2021, 38:2130-58. 10.1007\/s12325-021-01690-1","journal-title":"Adv Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1549","article-title":"New developments in the biology of fibroblast growth factors","volume":"14","author":"Ornitz DM","year":"2022","unstructured":"Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis. 2022, 14:e1549. 10.1002\/wsbm.1549","journal-title":"WIREs Mech Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3140673","article-title":"Oxidative stress and inflammation in hepatic diseases: current and future therapy","volume":"2017","author":"Reyes-Gordillo K","year":"2017","unstructured":"Reyes-Gordillo K, Shah R, Muriel P. Oxidative stress and inflammation in hepatic diseases: current and future therapy. Oxid Med Cell Longev. 2017, 2017:3140673. 10.1155\/2017\/3140673","journal-title":"Oxid Med Cell Longev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.06.016","article-title":"Chronic fatigue syndrome, the immune system and viral infection","volume":"26","author":"Bansal AS","year":"2012","unstructured":"Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. 2012, 26:24-31. 10.1016\/j.bbi.2011.06.016","journal-title":"Brain Behav Immun"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4020249","article-title":"An overview of lipid metabolism and nonalcoholic fatty liver disease","volume":"2020","author":"Pei K","year":"2020","unstructured":"Pei K, Gui T, Kan D, et al.. An overview of lipid metabolism and nonalcoholic fatty liver disease. Biomed Res Int. 2020, 2020:4020249. 10.1155\/2020\/4020249","journal-title":"Biomed Res Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-0881-3.00034-6","article-title":"Liver disease associated with viral infections","author":"Spengler U","year":"2011","unstructured":"Spengler U, Fischer HP, Caselmann WH. Liver disease associated with viral infections. Zakim and Boyer's Hepatology. 2011, 629-43. 10.1016\/B978-1-4377-0881-3.00034-6","journal-title":"Zakim and Boyer's Hepatology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-04404-2.10027-2","article-title":"Immune responses to viruses","author":"Mueller SN","year":"2009","unstructured":"Mueller SN, Rouse BT. Immune responses to viruses. Clin Immunol. 2009, 421-31. 10.1016\/B978-0-323-04404-2.10027-2","journal-title":"Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143473","article-title":"Abnormal metabolism in the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: mechanistic insights to chemoprevention","volume":"13","author":"Orabi D","year":"2021","unstructured":"Orabi D, Berger NA, Brown JM. Abnormal metabolism in the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: mechanistic insights to chemoprevention. Cancers (Basel). 2021, 13:10.3390\/cancers13143473","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli I","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019, 103:e1-e13. 10.1097\/TP.0000000000002480","journal-title":"Transplantation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson D","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021, 17:484-95. 10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23880","article-title":"Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores","volume":"35","author":"Yao R","year":"2021","unstructured":"Yao R, Zhu L, Wang J, et al.. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores. J Clin Lab Anal. 2021, 35:e23880. 10.1002\/jcla.23880","journal-title":"J Clin Lab Anal"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci. 2021, 22:10.3390\/ijms22052350","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2018.12.016","article-title":"Lifestyle interventions for non-alcoholic fatty liver disease","volume":"26","author":"Ahmed IA","year":"2019","unstructured":"Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci. 2019, 26:1519-24. 10.1016\/j.sjbs.2018.12.016","journal-title":"Saudi J Biol Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071166","article-title":"Combination therapies for nonalcoholic fatty liver disease","volume":"12","author":"Makri ES","year":"2022","unstructured":"Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med. 2022, 12:10.3390\/jpm12071166","journal-title":"J Pers Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque SM","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, et al.. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 2021, 3:100322. 10.1016\/j.jhepr.2021.100322","journal-title":"JHEP Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183540-unravelling-the-interplay-exploring-the-influence-of-previous-hepatitis-b-virus-hepatitis-a-virus-and-hepatitis-e-virus-infections-on-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:24Z","timestamp":1707509124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183540-unravelling-the-interplay-exploring-the-influence-of-previous-hepatitis-b-virus-hepatitis-a-virus-and-hepatitis-e-virus-infections-on-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,9]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.44969","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,9]]}}}